Acute myeloid leukemia and myelodysplastic syndromes in older patients.
about
Volasertib for AML: clinical use and patient considerationFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemiaA phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cellsAlternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaEffect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaSingle-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemiaBAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia.Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk featuresExpression and prognostic impact of lncRNAs in acute myeloid leukemia.Clofarabine: a new treatment option for patients with acute myeloid leukemia.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaAcute myeloid leukemia: survival analysis of patients at a university hospital of Paraná.Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.Estimating demand and unmet need for allogeneic hematopoietic cell transplantation in the United States using geographic information systems.Health care utilization and end-of-life care for older patients with acute myeloid leukemiaImmune dysregulation in myelodysplastic syndrome.MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia.Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaLow expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.Direct and indirect targeting of MYC to treat acute myeloid leukemiaHeritable polymorphism predisposes to high BAALC expression in acute myeloid leukemiaRandomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.Induction treatment of acute myeloid leukemia in an elderly patient with intramarrow injection/administration of cytarabine: first report of a case.The revolution of myelodysplastic syndromes.Treatment of acute promyelocytic leukemia for older patients.Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML PatientsAzacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.
P2860
Q26801131-EA57CEFE-57CB-4539-B733-81966C04B9C1Q27851545-FB0FFEB6-8BF7-4C77-8FBC-E572E4429F10Q27851689-BCF1E3CA-73CA-44E2-9BCD-3C468B018308Q28472176-78975E26-9044-440C-B141-72AC2C7C94E4Q33392683-F83D21A9-463C-4EFA-9AD1-E7F92960A2D5Q33406770-423D9E10-6663-4B7B-A453-765D7CAA6794Q33559964-73F4BDD2-4AF3-44E3-8EC9-9C7ADD4E56A2Q33859061-46DB5AC6-E38D-4E19-9904-EEA64A2C3C3EQ33872754-7B84281A-CAA4-4E73-8956-389B996E044DQ33897586-7F0248A2-D4AE-437E-995E-3600AC57E000Q33943277-808A308B-47DB-41D1-95E3-5BCDC61FFC4AQ33968372-062D5A37-100C-441D-BC7C-CBD4FD303FAEQ34004131-FBE66F42-A04C-4957-8C9D-FA6E2135C43BQ34162844-3144AAE0-13C5-429D-92E4-8808DE4942B1Q34179367-27FB485C-1D7D-49CF-B470-B33FF8D53B1EQ34293391-410B802C-0785-4B4B-937D-6001B62DAE4DQ34418965-83B99473-B40E-464F-8DEF-6ECCB3F559DFQ34541748-B9D5D225-F5AA-46F9-8706-38C786C956B0Q34766817-9F993902-836F-4105-B6D7-A7FA756C7C14Q34781553-5DC46DDC-7EE4-4ECC-9BC5-CB380C2386F1Q34831106-3207BC07-D263-4BFB-9DBD-D9682CA3E7CCQ34982576-8410C000-8670-4D11-B585-443148C04D4DQ35001132-6F607CBF-3437-4ABA-B8E9-A4F4DB60E445Q35018521-C0160210-C451-4504-8369-B08724A13A18Q35054850-5C68036E-F1EC-4EEA-B973-AA0057E08C4FQ35079660-AE22056F-EB2B-470F-9ACD-BCFA70D938ABQ35210617-7A4655BF-ACC0-440A-A848-18DA9615173DQ35564902-3BA19C0D-3792-43AC-AF74-1862585F9F40Q35567932-7C028EBF-573C-4723-B0AC-F7B33863F5EDQ35659883-2A5EBFEE-3556-44E6-9710-97040BABA4D9Q35742564-31D3E672-96E7-47BB-AB3A-4393DC1D7096Q35794120-C0AA44C2-7E5E-46EE-826E-330AF2B37965Q35798798-3FE8CD7E-A691-43A6-80DC-33C5BFB6380DQ35922032-11B130A1-03A4-40DB-8C64-E77E67CFAC46Q36366636-6B238741-1BF5-4976-88F9-AC3826B85F68Q36410505-2279C032-1638-4816-B405-A635803848B8Q36612553-6C3B7299-CBB6-46E7-9AF4-4AACE337B0D7Q36672084-6B20E351-A688-4508-9B74-0A00E8BDB722Q36721055-6E36B23D-319B-4021-B302-6B07F73048E3Q36805563-1B04467E-440A-47A7-8765-9422AB542A36
P2860
Acute myeloid leukemia and myelodysplastic syndromes in older patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Acute myeloid leukemia and myelodysplastic syndromes in older patients.
@ast
Acute myeloid leukemia and myelodysplastic syndromes in older patients.
@en
type
label
Acute myeloid leukemia and myelodysplastic syndromes in older patients.
@ast
Acute myeloid leukemia and myelodysplastic syndromes in older patients.
@en
prefLabel
Acute myeloid leukemia and myelodysplastic syndromes in older patients.
@ast
Acute myeloid leukemia and myelodysplastic syndromes in older patients.
@en
P356
P1476
Acute myeloid leukemia and myelodysplastic syndromes in older patients.
@en
P2093
Elihu Estey
P304
P356
10.1200/JCO.2006.10.2731
P407
P577
2007-05-01T00:00:00Z